Sugi Predict

Sugi Predict / Compounds / SCHEMBL50474

SCHEMBL50474

SCHEMBL50474

NC(=O)c1ccc2cc3n(c2c1)C=C1C=C1c1ccccc1-3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 1/20 0.39
▸ PDK2 Q15119 2/20 0.35
▸ BAZ2B Q9UIF8 1/20 0.35
▸ BAZ2A Q9UIF9 1/20 0.35
▸ PLAU P00749 1/20 0.35
▸ LCK P06239 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ BRPF1 P55201 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ JAK2 O60674 4/20 0.33
▸ JAK1 P23458 4/20 0.33
▸ TYK2 P29597 4/20 0.33
▸ JAK3 P52333 4/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ PIM3 Q86V86 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3236134 0.89 KMT2A (0.38) PDK2KDM4EALDH1A1HSD17B10KMT2A
SCHEMBL51324 0.81 KMT2A (0.38) KDM4EALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL3945086 0.77 RPS6KA3 (0.40) RPS6KA3PDK2BAZ2BBAZ2APLAU
SCHEMBL5329442 0.74 SRD5A2 (0.39) RPS6KA3BAZ2BBAZ2APLAUROCK2
SCHEMBL841837 0.72 RPS6KA3 (0.41) RPS6KA3PDK2BAZ2BBAZ2APLAU
SCHEMBL4822220 0.72 RPS6KA3 (0.40) RPS6KA3PDK2BAZ2BBAZ2APLAU
SCHEMBL50475 0.70 FGFR1 (0.36) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL5310375 0.68 RPS6KA3 (0.37) RPS6KA3LCKKDM4EBRD4ALDH1A1
SCHEMBL50820 0.68 RPS6KA3 (0.49) RPS6KA3BAZ2BBAZ2APLAULCK
SCHEMBL4823385 0.67 RPS6KA3 (0.41) RPS6KA3JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2209784-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2012-08-01 — — EP claimed
EP-2178878-B1 TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2012-03-28 — — EP claimed
EP-2178878-A1 TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2010-04-28 — — EP claimed
US-7642251-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-05 — — US claimed
US-20090130057-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-05-21 — — US claimed
WO-2009023487-A1 TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2009-02-19 — — WO claimed
US-20090042860-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-02-12 — — US claimed
EP-2518073-B1 Compounds for the treatment of Hepatitis C BRISTOL MYERS SQUIBB CO (US) 2015-08-26 — — EP disclosed
EP-2118109-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2014-11-26 — — EP disclosed
US-20140186299-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-07-03 — — US disclosed
US-20140045816-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-02-13 — — US disclosed
EP-2276764-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2013-07-24 — — EP disclosed
US-20130171098-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL MYERS SQUIBB CO (US) 2013-07-04 — — US disclosed
WO-2007136982-A1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-29 — — WO disclosed
US-20070275930-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-11-29 — — US disclosed
US-20070270405-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-11-22 — — US disclosed
US-20070270406-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-11-22 — — US disclosed
US-20070184024-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-08-09 — — US disclosed
WO-2007033032-A1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-22 — — WO disclosed
US-20070060565-A1 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270405-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS RPS6KA3 1970/4885PDK2 4377/4885BAZ2B 798/4885
US-20140045816-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS RPS6KA3 1970/4885PDK2 4377/4885BAZ2B 798/4885
US-20070184024-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors ZC3HAV1, CYP3A5, SLC10A1 RPS6KA3 2754/4885PDK2 4471/4885BAZ2B 770/4885
US-20070275930-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS RPS6KA3 1970/4885PDK2 4377/4885BAZ2B 798/4885
US-20070270406-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS RPS6KA3 1970/4885PDK2 4377/4885BAZ2B 798/4885
US-20070060565-A1 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors ZC3HAV1, CYP3A5, SLC10A1 RPS6KA3 2754/4885PDK2 4471/4885BAZ2B 770/4885
US-20140186299-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS RPS6KA3 1970/4885PDK2 4377/4885BAZ2B 798/4885
US-20090130057-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 RPS6KA3 1278/4885PDK2 2237/4885BAZ2B 3828/4885
US-20130171098-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS RPS6KA3 1970/4885PDK2 4377/4885BAZ2B 798/4885
US-20090042860-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 RPS6KA3 1278/4885PDK2 2237/4885BAZ2B 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.